Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02888054 · ClinicalTrials.gov registry record · Phase 1
Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence
A Phase 1 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02888054: Completed Phase 1 study, sponsored by Ardea Biosciences.
NCT02888054 is a Phase 1 study that has completed, run by Ardea Biosciences. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02888054, a Phase 1 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study will assess the bioequivalence (BE) of Lesinurad/Allopurinol Fixed-Dose Combination (FDC) Tablets and Coadministered Lesinurad and Allopurinol Tablets in Fed Healthy Adult Subjects
Primary Outcome
Cmax is the maximum observed concentration of a drug after administration
Interventions
- DRUG lesinurad 200 mg
- DRUG allopurinol 300 mg
- DRUG lesinurad/allopurinol 200/300 FDC tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-08-30 |
| Est. Completion | 2017-02-01 |
| Phase | Phase 1 |
What the finished NCT02888054 record still lists
NCT02888054 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 3 interventions - of which lesinurad 200 mg is the first listed.
NCT02888054 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02888054 about?
NCT02888054 is a clinical study titled "Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence". This study will assess the bioequivalence (BE) of Lesinurad/Allopurinol Fixed-Dose Combination (FDC) Tablets and Coadministered Lesinurad and Allopurinol Tablets in Fed Healthy Adult Subjects
What is the current status of trial NCT02888054?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2016-08-30. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT02888054?
The interventions under investigation include: lesinurad 200 mg (DRUG), allopurinol 300 mg (DRUG), lesinurad/allopurinol 200/300 FDC tablet (DRUG).
Who is sponsoring clinical trial NCT02888054?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02888054's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI